Phase IA Study of Atezolizumab in Urothelial Bladder Cancer

For patients who underwent radical cystectomy for bladder cancer, those with lower net worth incurred higher costs posttreatment.

Three additional clinical trials will study nadofaragene firadenovec-vncg for the treatment of patients with non-muscle invasive bladder cancer.

An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Sarah Lee, MD, MBA, discussed a study to better disaggregate the subgroup of Asian American patients with ovarian cancer.

Findings from a 3-year follow-up analysis found that nadofaragene firadenovec demonstrated durable, lasting results for patients with high-risk BCG-unresponsive non-muscle invasive bladder cancer.